Altimmune Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript
My name is Patrick Trucchio, and I am a Senior Biotech Analyst at H.C. Wainwright. It's my pleasure to introduce our next presenters, Vipin Garg, CEO; and Scott Harris, Chief Medical Officer of Altimmune, a clinical stage biopharmaceutical company focusing on developing treatments for obesity and liver disease. So I think maybe just to start, if we could talk about Altimmune's synthetic peptide technology platform, how did this come to be in its current form and what makes it differentiated from others in the market?
Yes. Thanks, Patrick. Thank you for having us. So as you know, we are developing two different therapeutic candidates, both peptide-based, based on synthetic peptide platform technology, and we have made specific modifications to this peptide -- to these peptides to accomplish a specific goal. For instance, to increase half-life of the peptide molecule. So our first candidate is ALT-801, or Pemvidutide. It is a GLP-1 glucagon dual agonist
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |